Pneumoconiosis Market Research Report, By Type (Asbestosis, Berylliosis, Byssinosis, Coal Workers Pneumoconiosis, Silicosis), Cause (Organic Dusts, Non-Organic Substances), Therapy (Diagnosis, Treatment), End User (Hospital) - Forecast till 2030

Pneumoconiosis Market Scenario:

The pneumoconiosis market is anticipated to reach USD 2,280.88 Million by 2030 at 9.40% CAGR during the forecast period 2022-2030.

Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.

Intended Audience

• Biotechnological institutes


• Pharmaceutical companies


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Medical Research Laboratories

by causes

Sources: WHO, annual reports, press release, white paper, and company presentation 

Segmentation

The pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.

On the basis of types, the pneumoconiosis market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.

On the basis of causes, the pneumoconiosis market is categorised into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.

On the basis of therapy, the pneumoconiosis market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.

On the basis of end users, the pneumoconiosis market is segmented into hospital, clinics, and others. 

Regional Analysis

America dominates the pneumoconiosis market owing to large patient population. Apart from this, increasing number of patients, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is equals around 36.5 million adults in the United States currently smoke cigarettes. Increasing smoking population increases the possibility of causing the disease. Additionally, increasing awareness among the people regarding different diagnostic procedures and well-developed technology has also contributed to the growth of the market.

Europe is the second largest pneumoconiosis market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and presence of huge opportunity in the market.

On the other hand, the Middle East & Africa has the least share in the pneumoconiosis market due to presence of poor economy especially in Africa region. Majority of the market of this region is held by Middle East due to well-developed healthcare sector and huge healthcare expenditure. 

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation 

Key players for pneumoconiosis market

The key players for the pneumoconiosis market Abbott (US) Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.).